• Indian market opportunity: Chronic kidney disease affects roughly 12.4 crore people in India, but only about 3 lakh out of an estimated 40 lakh patients needing dialysis currently receive it, which management expects will support a domestic segment CAGR of 20% to 24%.
• Financial growth targets: The company projects a 15% to 20% revenue CAGR over the next three to four years, stable operating margins that expand by a few basis points annually via scale efficiencies, and a steady-state ROCE of 20% to 22%.
• International pricing advantage: NephroPlus is leveraging its low domestic cost base of approximately $22 per treatment to expand into higher-priced international markets, including the Philippines ($100+), Uzbekistan ($70+), and Saudi Arabia ($250+).
• Three-pillar expansion strategy: Growth is driven by organic in-center volumes, clinic roll-ups in existing markets (adding 30 to 40 clinics annually in India), and larger lumpy opportunities such as new geography entries, PPP contracts, or M&A over a one- to two-year horizon.
• Lumpy pricing dynamics: Dialysis price hikes are not periodic but occur in lumpy intervals, as seen with a 35% CGHS price increase in India and a PhilHealth rate hike in the Philippines in October 2024.